NASDAQ · Health care

Trinity Biotech PLC (TRIB)

Trinity Biotech PLC reported revenue of $61.6M in fiscal 2024, up 8.3% from a year earlier. It posted a net loss of $31.8M. In fiscal 2024 capital spending exceeded operating cash flow by $4.6M. At December 31, 2024 it held $5.2M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on April 30, 2026.

Price

$6.76

-2.73% on the day · September 25, 2026

52-week range $6.62 to $52.50

Market cap

$5.5M

Revenue (FY2024)

$61.6M

+8.3% year on year

Net margin

-51.6%

What Trinity Biotech PLC does

Trinity Biotech PLC is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker TRIB.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2024	$61.6M	-$21.2M	-$31.8M	n/a	-$4.6M
2023	$56.8M	-$27M	-$24M	n/a	-$12.4M
2022	$62.5M	-$19.3M	-$41M	n/a	-$2M
2021	$81.1M	$3.9M	$875K	n/a	$11.4M
2020	$102M	$82K	-$6.4M	n/a	$20.6M
2019	$90.4M	-$24.1M	-$28.9M	n/a	$3.3M

Full financial statements: income, balance sheet and cash flow

Where TRIB ranks in Health care

Revenue$61.6M

#358 of 646 in Health care · Bottom 45%

Revenue growth+8.3%

#279 of 474 in Health care · Bottom 41%

Net margin-51.6%

#361 of 485 in Health care · Bottom 26%

Free cash flow margin-7.5%

#254 of 440 in Health care · Bottom 42%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

It paid out $5.1M in cash dividends, 23% of its net income.

Fiscal year	Per share	Paid out	Of profit
2015	n/a	$5.1M	23%

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Trinity Biotech PLC has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 9, 2026
Foreign issuer update 6-K
September 8, 2026
Foreign issuer update 6-K
August 28, 2026
Foreign issuer update 6-K
August 28, 2026
Form POS AM filing POS AM
August 27, 2026
Form AW filing AW
August 21, 2026
IPO registration (foreign issuer) (amended) F-1/A
August 17, 2026
Foreign issuer update 6-K
August 14, 2026
Foreign issuer update 6-K
July 22, 2026
Foreign issuer update 6-K
July 22, 2026
Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 6, the latest on April 8, 2026. Insider transactions on SEC

Who owns TRIB

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Perceptive Advisors LLC13D, may seek influence with 4 related filers	9.9%	3,424,019,957	May 4, 2026
Novus Diagnostics Ltd.13G, passive	5.99%	1,119,988	March 6, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about TRIB

What does Trinity Biotech PLC do?

Trinity Biotech PLC is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker TRIB.

Is Trinity Biotech PLC profitable?

No. In fiscal 2024 it reported a net loss of $31.8M on revenue of $61.6M.

How much revenue does Trinity Biotech PLC make?

In fiscal 2024 Trinity Biotech PLC reported revenue of $61.6M. That is 8.3% more than a year earlier.

When did Trinity Biotech PLC last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 30, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 9, 2026.

Similar companies

IDXX

Idexx Laboratories Inc

QDEL

QuidelOrtho Corp

LNTH

Lantheus Holdings, Inc.

Intellia Therapeutics, Inc.

Compare TRIB with

Compare TRIB with any company

Follow TRIB

Get an email when Trinity Biotech PLC files with the SEC: results, executive changes, material agreements and annual reports.

Follow TRIB: get an email when it files

Where the numbers come from

Financial figures are the values Trinity Biotech PLC tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.